ArticleMolecular medicine reports2015
Inhibition of liver fibrosis using vitamin A-coupled liposomes to deliver matrix metalloproteinase-2 siRNA in vitro.
Article in Molecular medicine reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Genomic medicine in hepatology: mechanisms and liver treatment strategies.Molecular medicine (Cambridge, Mass.) · 2025Review
- Anatomical Anal Stenosis after PPH: Insights from a Retrospective Study and Rat Model.International journal of molecular sciences · 2024Article
- Netrin-1 feedforward mechanism promotes pancreatic cancer liver metastasis via hepatic stellate cell activation, retinoid, and ELF3 signaling.Cell reports · 2023Article
- Potential Application of Small Interfering RNA in Gastro-Intestinal Tumors.Pharmaceuticals (Basel, Switzerland) · 2022Review
- New IMB16-4 Nanoparticles Improved Oral Bioavailability and Enhanced Anti-Hepatic Fibrosis on Rats.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Hepatic stellate cells specific liposomes with the Toll-like receptor 4 shRNA attenuates liver fibrosis.Journal of cellular and molecular medicine · 2021Article
- Efficient drug and gene delivery to liver fibrosis: rationale, recent advances, and perspectives.Acta pharmaceutica Sinica. B · 2020Review
- Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases.Cells · 2020Review
- siRNA- and miRNA-based therapeutics for liver fibrosis.Translational research : the journal of laboratory and clinical medicine · 2019Review
- Kaempferol attenuates liver fibrosis by inhibiting activin receptor-like kinase 5.Journal of cellular and molecular medicine · 2019Article
- In vitro inhibition of hepatic stellate cell activation by the autophagy-related lipid droplet protein ATG2A.Scientific reports · 2018Article
- Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis C.Scientific reports · 2016Article
- Dose-Dependent Antifibrotic Effect of Chrysin on Regression of Liver Fibrosis: The Role in Extracellular Matrix Remodeling.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic fibrosis is a common form of wound healing in response to chronic liver injuries and can lead to more serious complications, including mortality. It is well‑established that hepatic stellate cells (HSCs) are central mediators of hepatic fibrosis, and matrix metalloproteinase‑2 (MMP‑2) is important in the formation of liver fibrosis. In addition, HSCs are the primary cells secreting MMP‑2 and extracellular matrix, therefore, there has been increasing interest in developing agents with high selectivity towards HSCs. However, no clinical drugs based on MMP‑2, directed against HSCs, have been used to prevent fibrosis. Following consideration of the abundant vitamin A (VitA) receptors expressed on the cellular membrane of HSCs, the present study constructed VitA‑coupled liposomes (VitA‑lips) using dicyclohexylcarbodiimide‑1, 3‑diaminopentane condensation, rotatory film processing and ultrasonic oscillation. The results revealed that the liposomes exhibited low cytotoxicity and a suitable binding ability to MMP‑2 small interference (si)RNA. Furthermore, the liposomes effectively delivered MMP‑2 siRNA to the HSC‑T6 cells. When HSCs were treated with the liposomes carrying MMP‑2 siRNA (VitA‑lip‑MMP‑2 siRNA), the mRNA expression and activity of MMP‑2, and the protein expression levels of α‑smooth muscle actin and type I collagen were significantly reduced. These results suggested that inhibition of the expression of MMP‑2 in HSC‑T6 cells may contribute to preventing hepatic fibrosis, and provided experimental support to the development of specific drugs against MMP‑2 to prevent fibrogenesis in chronic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.